Skip to Main Content

The NASH ambitions of Cymabay Therapeutics (CBAY) hit a wall Tuesday with the negative outcome of a mid-stage clinical trial.

In the Phase 2 study, three oral doses of its lead drug, called seladelpar, all performed worse than a placebo, based on a non-invasive imaging test that measures decreases in liver fat. The study had enrolled 181 patients with moderate stage of NASH and treated them for 12 weeks.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!